Morpholine → HCID 60164657, compound
Reaction equation
CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.[F:23][C:24]1[CH:32]=[CH:31][C:30]([CH:33]2[C:46]3[CH:45]=[CH:44][C:43]4[C:38](=[N:39][CH:40]=[CH:41][CH:42]=4)[C:37]=3[NH:36][S:35](=[O:48])(=[O:47])[N:34]2[CH3:49])=[CH:29][C:25]=1[C:26]([OH:28])=O.[NH:50]1[CH2:55][CH2:54][O:53][CH2:52][CH2:51]1.CCN(C(C)C)C(C)C>C(Cl)Cl.O>[F:23][C:24]1[CH:32]=[CH:31][C:30]([CH:33]2[C:46]3[CH:45]=[CH:44][C:43]4[C:38](=[N:39][CH:40]=[CH:41][CH:42]=4)[C:37]=3[NH:36][S:35](=[O:47])(=[O:48])[N:34]2[CH3:49])=[CH:29][C:25]=1[C:26]([N:50]1[CH2:55][CH2:54][O:53][CH2:52][CH2:51]1)=[O:28]Participants
7
Reactant 4
Product 1
Reagents, catalysts & solvents 2
Procedure
TBTU (49.73 mg, 0.15 mmol) was added to a suspension of 2-fluoro-5-(2-methyl-3,3-dioxo-1,2,3,4-tetrahydro-3λ*6*-thia-2,4,5-triaza-phenanthren-1-yl)-benzoic acid 424 (60 mg, 0.15 mmol) in DCM (1 ml) and the mixture was stirred at room temperature for 20 min. Morpholine (13.6 μl, 0.15 mmol) and DIPEA (25.6 μl, 0.15 mmol) were added and the mixture was stirred at room temperature for 3 h. The mixture was diluted with water (1 ml) and the mixture was extracted with DCM (3 ml). The organic phase was concentrated in vacuo. The crude residue was purified by preparative HPLC (acidic conditions 1) to give the title compound (32 mg, 45%).
Workup
- stirringthe mixture was stirred at room temperature for 3 h
- extractionthe mixture was extracted with DCM (3 ml)
- concentrationThe organic phase was concentrated in vacuo
- customThe crude residue was purified by preparative HPLC (acidic conditions 1)
Sources & evidence
- ORD record
- ord-ef07806ca43f4e3fb423a6f1ee904027
- Source dataset
- uspto-grants-2015_08
- Patent number
- US09102688B2
Reaction notes
Loading…